Cytotoxicity of 5-fluorouracil: Effect on endothelial differentiation via cell cycle inhibition in mouse embryonic stem cells

Toxicology in Vitro

Volumn 23, Issue 4, 2009, Pages 719-727

  Kim, Gi Dae ^a   Rhee, Gyu Seek ^b   Chung, Hyung Min ^c   Chee, Kew Mahn ^a   Kim, Gi Jin ^c  

^a Korea University   (South Korea)

^b Korea Food and Drug Administration   (South Korea)

^c Hallym Unversity College of Medicine   (South Korea)

Author keywords

5 Fluorouracil; cDNA microarray; Cell cycle; Cytotoxicity; Differentiation; Mouse embryonic stem cells; Proliferation; Viability

Indexed keywords

CD31 ANTIGEN; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; FLUOROURACIL; OCTAMER TRANSCRIPTION FACTOR 4; PROBUCOL; PROTEIN P53;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA MICROARRAY; DRUG CYTOTOXICITY; EMBRYO; EMBRYONIC STEM CELL; EMBRYOTOXICITY; ENDOTHELIUM CELL; GENE EXPRESSION; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, CD31; ANTIMETABOLITES, ANTINEOPLASTIC; CELL CYCLE; CELL DIFFERENTIATION; CELLS, CULTURED; EMBRYONIC STEM CELLS; ENDOTHELIAL CELLS; FLUOROURACIL; G1 PHASE; GENE EXPRESSION PROFILING; MICE; S PHASE;

EID: 67349179060     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2009.02.012     Document Type: Article

References (35)

1. Becker K.A., Ghule P.N., Therrien J.A., Lian J.B., Stein J.L., Wijnen A.J., and Stein G.S. Self-renewal of human embryonic stem cells is supported by a shortened G1 cell cycle phase. J. Cell. Physiol. 209 (2006) 883-893
2. Bremer S., and Hartung T. The use of embryonic stem cells for regulatory developmental toxicity testing in vitro - the current status of test development. Curr. Pharm. Des. 10 (2004) 2733-2747
3. Brown N.A., Spielmann H., Bechter R., Flint O.P., Freemen S.J., Jelinek R.J., Koch E., Nau H., Newall D.R., Palmer A.K., Renault J.Y., Repetto M.F., Vogel R., and Wiger R. Screening chemicals for reproductive toxicity: the current alternatives. ATLA 23 (1995) 868-882
4. Burdon T., Smith A., and Savatier P. Signalling, cell cycle and pluripotency in embryonic stem cells. Trends Cell Biol. 12 (2002) 432-438
5. Dimery I.W., and Hong W.K. Overview of combined modality therapies for head and neck cancer. J. Natl. Cancer Inst. 85 (1993) 95-111
6. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., and Trent J.M. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
7. Evans M.J., and Kaufman M.H. Establishment in culture of pluripotential cells from mouse embryos. Nature 292 (1981) 154-156
8. Fumoto S., Shimokuni T., Tanimoto K., Hiyama K., Otani K., Ohtaki M., Hihara J., Yoshida K., Hiyama E., Noguchi T., and Nishiyama M. Selection of a novel drug-response predictor in esophageal cancer: a novel screening method using microarray and identification of IFITM1 as a potent marker gene of CDDP response. Int. J. Oncol. 32 (2008) 413-423
9. Gartel A.L., Goufman E., Tevosian S.G., Shih H., Yee A.S., and Tyner A.L. Activation and repression of p21 (WAF1/CIP1) transcription by RB binding proteins. Oncogene 17 (1998) 3463-3469
10. Gunji W., Kai T., Takahashi Y., Maki Y., Kurihara W., Utsugi T., Fujimori F., and Murakami Y. Global analysis of the regulatory network structure of gene expression in Saccharomyces cerevisiae. DNA Res. 11 (2004) 163-177
11. Heo J., Lee J., Chu I., Takahama Y., and Thorgeirsson S.S. Spontaneous differentiation of mouse embryonic stem cells in vitro: characterization by global gene expression profiles. BBRC 332 (2005) 1061-1069
12. Heuer J., Bremer S., Pohl I., and Spielmann H. Development of an in vitro embryotoxicity test using murine embryonic stem cell cultures. Toxicol. In Vitro 7 (1993) 551-556
13. Hong Y., and Stambrook P.J. Restoration of an absent G1 arrest and protection from apoptosis in embryonic stem cells after ionizing radiation. Proc. Natl. Acad. Sci. USA 101 (2004) 14443-14448
14. Kaneko M., Hayashi J., Saito I., and Miyasaka N. Probucol downregulates E-selectin expression on cultured human vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 1047-1051
15. Kim G.D., Kim G.J., Seok J.H., Chung H., Chee K., and Rhee G. Differentiation of endothelial cells derived from mouse embryoid bodies: a possible in vitro vasculogenesis model. Toxicol. Lett. 180 (2008) 166-173
16. Kim S., and von Recum H. Endothelial stem cells and precursors for tissue engineering: cell source, differentiation, selection, and application. Tissue Eng. Part B. Rev. 14 (2008) 133-147
17. Kinhult S., Albertsson M., Eskilsson J., and Cwikiel M. Effects of probucol on endothelial damage by 5-fluorouracil. Acta Oncol. 42 (2003) 304-308
18. Kita T., Nagano Y., Yokode M., Ishii K., Kume N., Ooshima A., Yoshida H.h., and Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc. Natl. Acad. Sci. USA 84 (1987) 5928-5931
19. Knight A. Systematic reviews of animal experiments demonstrate poor human clinical and toxicological utility. Altern. Lab. Anim. 35 (2007) 641-659
20. Lane D.P. Cancer: p53, guardian of the genome. Nature 358 (1992) 15-16
21. Lewin F., Skog S., Tribukait B., and Ringborg U. Effect of 5-fluorouracil on the cell growth and cell cycle kinetics of a mouse ascites tumor growing in vivo. Acta Oncol. 26 (1987) 125-131
22. Martin G.R. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc. Natl. Acad. Sci. USA 12 (1981) 7634-7638
23. Mori N., Glunde K., Takagi T., Raman V., and Bhujwalla Z.M. Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res. 67 (2007) 11284-11290
24. Parker W.B., and Cheng Y.C. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol. Therapeut. 48 (1990) 381-395
25. Pinedo H.M., and Peters G.F. Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol. 6 (1988) 1653-1664
26. Ramalho-Santos M., Yoon S., Matsuzaki Y., Mulligan R.C., and Melton D.A. "Stemness" transcriptional profiling of embryonic and adult stem cells. Science 298 (2002) 597-600
27. Rohwedel J., Guan K., Hegert C., and Wobus A.M. Embryonic stem cells as an in vitro model for mutagenicity, cytotoxicity and embryotoxicity studies: present state and future prospects. Toxicol. In Vitro 15 (2001) 741-753
28. Scholz G., Pohl I., Genschow E., Klemm M., and Spielmann H. Embryotoxicity screening using embryonic stem cells in vitro: correlation to in vivo teratogenicity. Cells Tissues Organs 165 (1999) 203-211
29. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13 (1999) 1501-1512
30. Shimizu N., Aoyama H., Hatakenaka N., Kaneda M., and Teramoto S. An in vitro screening system for characterizing the cleft palate-inducing potential of chemicals and underlying mechanisms. Reprod. Toxicol. 15 (2001) 665-672
31. Spielmann H., Pohl I., Doering B., Liebsch M., and Moldenhauer F. The embryonic stem cell test, an in vitro embryotoxicity test using two permanent mouse cell lines: 3T3 fibroblasts and embryonic stem cells. In Vitro Toxicol. 10 (1997) 119-127
32. Stead E., White J., Faast R., Conn S., Goldstone S., Rathjen J., Dhingra U., Rathjen P., Walker D., and Dalton S. Pluripotent cell division cycles are driven by ectopic Cdk2, cyclin A/E and E2F activities. Oncogene 21 (2002) 8320-8333
33. Steele C.E., New D.A., Ashford A., and Copping G.P. Teratogenic action of hypolipidemic agents: an in vitro study with postimplantation rat embryos. Teratology 28 (1983) 229-236
34. Vittet D., Prandini M.H., Berthie R., Schweitzer A., Martin-Sisteron H., Uzan G., and Dejana E. Embryonic stem cells differentiate in vitro to endothelial cells through successive maturation steps. Blood 88 (1996) 3424-3431
35. Watts M.E., Woodcock M., Arnold S., and Chaplin D.J. Effects of novel and conventional anti-cancer agents on human endothelial permeability: influence of tumour secreted factors. Anticancer Res. 17 (1997) 71-75